Ropes & Gray Advises on 3 of the Top 10 Biopharmaceutical Licensing Deals in 2023
March 27, 2024
March 27, 2024
BOSTON, Massachusetts, March 27 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray represented clients in three of the top 10 and four of the top 20 biopharmaceutical licensing deals measured by deal value, according to an analysis by DealForma. Ropes & Gray licensing partners advised clients in these top deals for an aggregate value of $14.7 billion. Among the deals Ropes & Gray was involved in were the following:
* Pfizer in a strategic . . .
Ropes & Gray represented clients in three of the top 10 and four of the top 20 biopharmaceutical licensing deals measured by deal value, according to an analysis by DealForma. Ropes & Gray licensing partners advised clients in these top deals for an aggregate value of $14.7 billion. Among the deals Ropes & Gray was involved in were the following:
* Pfizer in a strategic . . .